

# Competitive Pipeline Report — Johnson & Johnson

Run date (UTC): 2026-01-08

Pipeline source URL	https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
Stored pipeline PDF	sources/jnj/2026-01-08.pdf
Pipeline SHA256	7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04
Programs extracted	101
Recovered baseline	No
Doc unchanged / reused	Yes
Inventory CSV	reports/jnj/2026-01-08.programs.csv
Evidence pack	reports/jnj/2026-01-08.evidence.json

## J&J Pipeline Update: No Major Changes Detected; Ongoing CT.gov Corroboration and EDGAR Monitoring

This month's analysis of Johnson & Johnson's pipeline reveals no detected additions, removals, or phase changes. Our primary pipeline intelligence sources indicate a static period for J&J's R&D portfolio. ClinicalTrials.gov corroboration for queried assets shows consistent phase reporting, with no discrepancies identified, further supporting the stability observed. No pipeline-related disclosures were identified in recent SEC EDGAR filings. We continue to closely monitor key assets and the broader competitive landscape for any emerging developments.

### Top changes (ranked)

No ranked changes generated.

### Pipeline snapshot (counts by phase)

Phase	Count
Unknown	101
Total	101

### Corroboration summary

ClinicalTrials.gov: matches for 25/101 programs; phase mismatches: 0.

SEC EDGAR: 0 filings with pipeline-related signals since 2026-01-08.

## Appendix — Full pipeline inventory

Includes source page for manual verification and CT.gov phase flag when available.

Asset	Indication	Phase	Page	CT.gov phase	Flag
AKEEGA (niraparib/abiraterone)	M1 Metastatic Castration-Sensitive Prostate Cancer			Phase 3	ok
Bleximenib	Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine			Phase 3	ok
Bleximenib	Relapsed Refractory Acute Myeloid Leukemia			Phase 3	ok
CABENUVA	HIV Adolescents				none
CAPLYTA (lumateperone)	Adjunctive Treatment for Major Depressive Disorder				none
CAPLYTA (lumateperone)	Bipolar Mania				none
CAPLYTA (lumateperone)	Pediatric Psychiatric Indications				none
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma TNI				ok
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma Transplant Eligible vs ASCT				ok
DARZALEX (daratumumab)	Smoldering Multiple Myeloma			Phase 2	ok
DARZALEX (daratumumab)	Frontline multiple myeloma transplant ineligible			Phase 2	ok
ERLEADA (apalutamide)	Localized Prostate Cancer			Phase 2	ok
ERLEADA (apalutamide)	High Risk Prostate Cancer			Phase 2	ok
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis				none
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis Pediatrics				none
IMBRUVICA (ibrutinib)	Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)			Phase 2	ok
IMBRUVICA (ibrutinib)	Frontline Mantle Cell Lymphoma			Phase 2	ok
INLEXZO (gemcitabine intravesical)	Non Muscle Invasive Bladder Cancer				none
INLEXZO (gemcitabine intravesical)	Non Muscle Invasive Bladder Cancer BCG-naïve High Risk				none
INLEXZO (gemcitabine intravesical)	High Risk Non Muscle Invasive Bladder Cancer BGC Experienced				none
ITI-1284	Generalized Anxiety Disorder				none
ITI-1284	Alzheimer's Disease-Related Psychosis				none
ITI-1284	Alzheimer's Disease-Related Agitation				none
JNJ-0387	Solid Tumors				none
JNJ-0631 (ARX305)	Renal Cancer				none
JNJ-0683 (ARX788)	Breast Cancer				none
JNJ-1493	Hematological Malignancies				none
JNJ-1887 sCD59	Geographic Atrophy				none
JNJ-1900 (NBTXR3)	Head and Neck Cancer				none
JNJ-1900 (NBTXR3)	Lung Cancer				none
JNJ-2056 (tau active immunotherapy)	Alzheimer's Disease				none
JNJ-2638	Gastrointestinal Cancer				none
JNJ-2761	Multiple Myeloma				none
JNJ-3413	Lymphoma				none

Asset	Indication	Phase	Page	CT.gov phase	Flag
JNJ-4496	Hematological Malignancies				none
JNJ-4680	Lung Cancer				none
JNJ-4681	Hematological Malignancies				none
JNJ-4804 Co-antibody Therapy	Ulcerative Colitis				none
JNJ-4804 Co-antibody Therapy	Psoriatic Arthritis				none
JNJ-4804 Co-antibody Therapy	Crohn's Disease				none
JNJ-4916	Lung Cancer				none
JNJ-5108	Immunological Diseases				none
JNJ-5120	Major Depressive Disorder				none
JNJ-5322	Multiple Myeloma				none
JNJ-5939	Atopic Dermatitis				none
JNJ-6420	Prostate Cancer				none
JNJ-6848	Immunological Diseases				none
JNJ-7446	Lung Cancer				none
JNJ-7528	Atopic Dermatitis				none
JNJ-8177 (ARX517)	Prostate Cancer				none
JNJ-8377	Lymphoma				none
JNJ-8543	Hematological Malignancies				none
JNJ-9401	Prostate Cancer				none
JNJ-9530	Hematological Malignancies				none
JNJ-9892	Hematological Malignancies				none
JNJ-9968	Hematological Malignancies				none
RPGR Gene Therapy	Retinitis Pigmentosa				none
RYBREVANT (amivantamab)	Frontline Non Small Cell Lung Cancer in combination with chemotherapy			Phase 3	ok
RYBREVANT (amivantamab)				Phase 3	ok
RYBREVANT (amivantamab)	Colorectal Cancer			Phase 3	ok
RYBREVANT (amivantamab)	Colorectal Cancer 2L			Phase 3	ok
SIMPONI (golimumab)	Pediatric Ulcerative Colitis				none
SIRTURO	Leprosy				none
SIRTURO	Tuberculosis Long Acting				none
SPRAVATO (esketamine)	Treatment Resistant Depression monotherapy				none
SPRAVATO (esketamine)	Major Depressive Disorder with Suicidal Ideation Pediatrics				none
STELARA (ustekinumab)	Pediatric Crohn's Disease				none
STELARA (ustekinumab)	Pediatric Ulcerative Colitis				none
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma CD38 exposed			Phase 3	ok
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma A-CD38 Naïve			Phase 3	ok

Asset	Indication	Phase	Page	CT.gov phase	Flag
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma CD38 exposed			Phase 3	ok
TALVEY + TECVAYLI	TIE NDMM in combination with DR			Phase 3	ok
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma			Phase 3	ok
TAR-210 (RIS/erdafitinib)	Intravesical Delivery System for Localized Bladder Cancer				none
TECVAYLI (teclistamab)	Multiple Myeloma 1-3PLs			Phase 3	ok
TECVAYLI (teclistamab)	TE NDMM maintenance			Phase 3	ok
TECVAYLI (teclistamab)	TIE NDMM in combination with DR			Phase 3	ok
TECVAYLI (teclistamab)	Relapsed Refractory Multiple Myeloma CD38 exposed			Phase 3	ok
TREMFYA (guselkumab)	Pediatric Juvenile Psoriatic Arthritis				none
TREMFYA (guselkumab)	Pediatric Psoriasis				none
TREMFYA (guselkumab)	Psoriatic Arthritis Structural Damage				none
TREMFYA (guselkumab)	Ulcerative Colitis Subcutaneous Induction				none
TREMFYA (guselkumab)	Pediatric Ulcerative Colitis				none
UPTRAVI (selexipag)	Pediatric Pulmonary Arterial Hypertension				none
icotrokinra	Psoriasis				none
icotrokinra	Psoriatic Arthritis				none
icotrokinra	Ulcerative Colitis				none
macitentan	Pulmonary Arterial Hypertension 75mg				none
milvexian (Factor Xla)	Secondary Stroke Prevention				none
milvexian (Factor Xla)	Acute Coronary Syndrome				none
milvexian (Factor Xla)	Atrial Fibrillation				none
nipocalimab	Warm Autoimmune Hemolytic Anemia				none
nipocalimab	Sjogren's Disease				none
nipocalimab	Hemolytic Disease of the Fetus and Newborn				none
nipocalimab	Fetal and Neonatal Alloimmune Thrombocytopenia				none
nipocalimab	Systemic Lupus Erythematosus				none
nipocalimab	Idiopathic Inflammatory Myopathy				none
nipocalimab	Chronic Inflammatory Demyelinating Polyneuropathy				none
pasritamig	Prostate Cancer			Phase 3	ok
posdinemab	Alzheimer's Disease				none
seltorexant	Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms				none